You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Colorectal cancer prevention in inflammatory bowel disease and the role of 5aminosalicylic acid: A clinical review and update

Rubin, David T.1,*; Cruz‐Correa, Marcia R.2; Gasche, Christoph3; Jass, Jeremy R.4; Lichtenstein, Gary R.5; Montgomery, Elizabeth A.6; Riddell, Robert H.7; Rutter, Matthew D.8; Ullman, Thomas A.9; Velayos, Fernando S.10; Itzkowitz, Steven9

Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20297
Clinical Reviews: Colorectal Cancer in IBD: Clinical Review
Abstract

A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5‐aminosalicylic acid. Specific topics that were addressed included: the epidemiology of colorectal cancer, including an assessment of risk factors and the impact of colonoscopy on colorectal cancer incidence and mortality; the origin and evolution of dysplasia nomenclature and the natural history of dysplasia; review of the experience of St. Mark's Hospital (London) as gleaned from its surveillance database; mechanisms by which 5‐aminosalicylic acid is thought to exert a chemopreventive effect; the potential future role of 5‐aminosalicylic acid in chemopreventive strategies; chemoprevention in familial adenomatous polyposis; and other future research directions. This article provides a comprehensive overview of the issues discussed and should act as a guide to shaping the design of future studies in this area.

Author Information

1University of Chicago Medical Center, Chicago, Illinois

2University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico

3Medical University of Vienna, Vienna, Austria

4St. Mark's Hospital, Harrow, United Kingdom

5University of Pennsylvania, Philadelphia, Pennsylvania

6Johns Hopkins University School of Medicine, Baltimore, Maryland

7Mount Sinai Hospital, Toronto, Ontario, Canada

8University Hospital of North Tees, Stockton on Tees, United Kingdom

9Mount Sinai School of Medicine, New York, New York

10University of California, San Francisco, California

*From the Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637

Email: drubin@medicine.bsd.uchicago.edu

Received 31 August 2007; Accepted 4 September 2007

Published online 11 October 2007 in Wiley Online Library (wileyonlinelibrary.com).

Grant sponsor: Shire Pharmaceuticals Inc., Wayne, Pennsylvania.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.